
Zentalis Pharmaceuticals (ZNTL) Stock Forecast & Price Target
Zentalis Pharmaceuticals (ZNTL) Analyst Ratings
Bulls say
Zentalis Pharmaceuticals is viewed favorably because interim DENALI data suggest azenosertib can generate meaningful, biomarker-enriched benefit in Cyclin E1-positive platinum-resistant ovarian cancer, where median overall survival reached about 15.8 to 15.9 months versus 7.5 months in Cyclin E1-negative patients, alongside an updated ORR of 37.2%. The investment case is strengthened by improved tolerability signals, including roughly a 50% reduction in discontinuations and no new safety signals, which supports the 400 mg QD 5:2 dose and the broader non-chemotherapy strategy. Financially, Zentalis ended Q3 with $228.9M in cash, cash equivalents and marketable securities, and management believes that is sufficient to fund operations into 1H:28, providing runway through key upcoming readouts.
Bears say
Zentalis Pharmaceuticals is viewed negatively because its core value driver, azenosertib, still faces major clinical and regulatory risk, including the possibility that it may not prove efficacious or could generate safety signals serious enough to halt development. The company also depends heavily on a single lead asset for future growth, so any setback in the program would materially weaken its outlook and undermine confidence in its ability to advance from a clinical-stage biopharmaceutical company into a commercial one. Even if development succeeds, azenosertib may still struggle against current and future therapies, and the company may be unable to achieve sales estimates, leaving its long-term revenue potential uncertain.
This aggregate rating is based on analysts' research of Zentalis Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Zentalis Pharmaceuticals (ZNTL) Analyst Forecast & Price Prediction
Start investing in Zentalis Pharmaceuticals (ZNTL)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Zentalis Pharmaceuticals (ZNTL) Forecast
Zentalis Pharmaceuticals (ZNTL) Analyst Forecast & Price Prediction
Start investing in Zentalis Pharmaceuticals (ZNTL)
Order type
Buy in
Order amount
Est. shares
0 shares